Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
Sponsor: The First Hospital of Jilin University
Summary
This single-center, stratified randomized double-blind trial tests tegileridine, a new pain drug, for pain relief after weight-loss surgery. Researchers will compare tegileridine with standard opioid pain medicine. Eligible patients having bariatric surgery will be randomly assigned to one of the two treatment groups. Patients and study teams will not know which treatment each participant receives. Participants will be grouped based on whether they have obstructive sleep apnea (OSA). The primary measurement is postoperative recovery quality in the first 24 hours after surgery using the QoR-15 survey. The study will also track pain scores, rescue pain medication use, and drug side effects for 7 days after surgery. There is no guaranteed benefit for participants. Study pain medicines may cause side effects. Doctors will provide rescue treatment for uncontrolled pain.
Official title: Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tapentadol in Patients Undergoing Bariatric Surgery
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
148
Start Date
2026-10-01
Completion Date
2027-10-01
Last Updated
2026-09-28
Healthy Volunteers
No
Interventions
Tegileridine (tegileridine fumarate injection, IV)
Tegileridine will be given to participants for postoperative pain relief after bariatric surgery.
Sufentanil
Sufentanil, a standard opioid analgesic, will be given to participants to manage postoperative pain following bariatric surgery.